Parkinson's disease

@article{Kalia2015ParkinsonsD,
  title={Parkinson's disease},
  author={L. V. Kalia and A. Lang},
  journal={The Lancet},
  year={2015},
  volume={386},
  pages={896-912}
}
Parkinson's disease is a neurological disorder with evolving layers of complexity. It has long been characterised by the classical motor features of parkinsonism associated with Lewy bodies and loss of dopaminergic neurons in the substantia nigra. However, the symptomatology of Parkinson's disease is now recognised as heterogeneous, with clinically significant non-motor features. Similarly, its pathology involves extensive regions of the nervous system, various neurotransmitters, and protein… Expand
2 Aetiology and Pathogenesis of Parkinson ’ s Disease
Parkinson’s disease (PD) is one of the commonest neurodegenerative disorders, with a cumulative life-time incidence of 2%. The diagnosis is typically made via the clinical features of bradykinesia inExpand
Parkinson's disease
TLDR
It is shown how personalised management of Parkinson's disease can be optimised and requires a multidisciplinary team approach, including a growing repertoire of non-pharmacological interventions. Expand
Neuroimaging Advances in Parkinson's Disease and Atypical Parkinsonian Syndromes
TLDR
An updated presentation of well-established and emerging neuroimaging biomarkers are reviewed from the following modalities: structural magnetic resonance imaging (MRI), diffusion-weighted and diffusion tensor MRI, resting-state and task-based functional MRI, proton magnetic resonance spectroscopy, and single photon emission computed tomography. Expand
Non-motor symptoms in Parkinson’s disease : modeling and mechanisms
TLDR
A mouse model of PD is developed and validated, characterized by a bilateral partial degeneration of the dopaminergic system achieved through intra-striatal injection of 6-hydroxydopamine (6-OHDA), and it is shown that the 6-OHda lesion impairs olfactory discrimination, disrupts circadian rhythm, causes long-term memory deficits, as well as depressionand anxiety-like behaviors. Expand
Role of Neuroimaging on Differentiation of Parkinson's Disease and Its Related Diseases.
TLDR
A diagnostic approach is provided for the differential diagnosis of PD and its related diseases in clinical practice using morphological imaging modalities (conventional MR imaging and neuromelanin MR imaging) and functional imagingmodalities that are clinically available in most hospitals. Expand
Clinical and Imaging Markers of Prodromal Parkinson's Disease
TLDR
The approach to prodromal PD is reviewed, with an emphasis on clinical and imaging markers and results from the neuroimaging study, a retrospective evaluation of a cohort of 39 participants who underwent DAT-SPECT scan as part of their follow up. Expand
Challenges in the diagnosis of Parkinson's disease
TLDR
Parkinson's disease is evolving from a clinical to a biomarker-supported diagnostic entity, for which earlier identification is possible, different subtypes with diverse prognosis are recognised, and novel disease-modifying treatments are in development. Expand
Epidemiology of Parkinson’s disease
TLDR
A recent revision of the diagnostic criteria excludes postural instability as a fourth hallmark and defines supportive criteria, absolute exclusion criteria and red flags, and Revised diagnostic criteria are expected to improve the clinician´s accuracy in diagnosing PD. Expand
Two-hundred Years Later: Is Parkinson's Disease a Single Defined Entity?
TLDR
Current evidence appears to be insufficient at this moment to clarify the hypothesis that Parkinson's disease may be not one well-defined entity but several different diseases encompassed as a levodopa-responsive Parkinsonism. Expand
Recent developments in the treatment of Parkinson's Disease
TLDR
This review provides an overview of the novel therapeutic approaches that are close to, or are already in, clinical trials for Parkinson's disease and those that are aimed towards slowing pathology, reducing neuronal loss, and attenuating disease course. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 174 REFERENCES
Parkinson's disease and parkinsonism: neuropathology.
  • D. Dickson
  • Medicine
  • Cold Spring Harbor perspectives in medicine
  • 2012
TLDR
Given the population frequency of PD, α-synuclein pathology similar to that in PD, but not accompanied by neuronal loss, is relatively common (10% of people over 65 years of age) in neurologically normal individuals, leading to proposed staging schemes for PD progression. Expand
The history of Parkinson's disease: early clinical descriptions and neurological therapies.
  • C. Goetz
  • Medicine
  • Cold Spring Harbor perspectives in medicine
  • 2011
TLDR
Historically important anatomical, biochemical, and physiological studies identified additional pharmacological and neurosurgical targets for Parkinson's disease and allow modern clinicians to offer an array of therapies aimed at improving function in this still incurable disease. Expand
Changing the research criteria for the diagnosis of Parkinson's disease: obstacles and opportunities
TLDR
The time has come to establish a research framework that could lead to new diagnostic criteria for Parkinson's disease, and this work proposes the establishment of three tiers encompassing clinical features, pathological findings, and genetics or molecular mechanisms. Expand
The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease.
  • W. Gibb, A. Lees
  • Medicine
  • Journal of neurology, neurosurgery, and psychiatry
  • 1988
TLDR
Associated pathological findings suggest that cases of incidental Lewy body disease are presymptomatic cases of Parkinson's disease, and confirm the importance of age (time) in the evolution of the disease. Expand
Identifying prodromal Parkinson's disease: Pre‐Motor disorders in Parkinson's disease
TLDR
The evidence for the utility of olfaction, RBD, autonomic markers, visual changes, mood disorders, and cognitive loss as markers of prodromal PD and the potential sensitivity and specificity of these markers are summarized. Expand
Parkinson's Disease and alpha-Synuclein Expression
TLDR
The clinical impact of alpha-synuclein locus multiplications, and the implications that this has for Parkinson's disease pathogenesis are outlined, and potential strategies for disease-modifying therapies are discussed. Expand
What genetics tells us about the causes and mechanisms of Parkinson's disease.
TLDR
An impressive set of data in different model systems strongly suggest that mitochondrial dysfunction plays a central role in clinically similar, early-onset autosomal recessive PD forms caused by parkin and PINK1, and possibly DJ-1 gene mutations. Expand
A tale on animal models of Parkinson's disease
  • E. Bézard, S. Przedborski
  • Psychology, Medicine
  • Movement disorders : official journal of the Movement Disorder Society
  • 2011
TLDR
During this journey of 25 years, both the significant contributions of the Parkinson's disease models and hurdles that remain to be overcome to one day cure this neurological disease are discussed. Expand
The synaptic pathology of α-synuclein aggregation in dementia with Lewy bodies, Parkinson’s disease and Parkinson’s disease dementia
TLDR
If presynaptic α-synuclein aggregation, not neuronal loss, is the key issue of the neurodegenerative process, then PD and DLB may eventually be treatable in the future and stem cell transplants are of limited use. Expand
Disease duration and the integrity of the nigrostriatal system in Parkinson's disease.
TLDR
The extent of nigrostriatal degeneration in patients with Parkinson's disease at different disease durations from time of diagnosis is investigated and loss of dopaminergic markers in the dorsal putamen occurs rapidly and is virtually complete by 4 years post-diagnosis. Expand
...
1
2
3
4
5
...